Fig. 4
From: Antitumor effects of erlotinib in combination with berberine in A431 cells
Berberine combined with erlotinib inhibited tumor growth in vivo. Body weights (a) and tumor volumes (b) of A431 xenograft tumors treated with vehicle control, BBR (15 mg/kg), erlotinib (25 mg/kg), and BBR plus erlotinib. (c) Representative photographs of tumor tissues. (d) Tumor weights. (e) Representative image of IHC (original magnification ×400). (f) Immunohistochemical staining analysis of pEGFR, pERK1/2, and Ki67 in A431 xenograft tumors. (g) The expression levels of EGFR and pEGFR in A431 xenograft tumors. Data were analyzed using one-way ANOVA and Student’s t-test, *P < 0.05; **P < 0.01; ***P < 0.001 vs. combination-therapy group. #P < 0.05; ##P < 0.01; ###P < 0.001 vs. control